Company Performance Metrics
- Martyn Hilton: Chief Global Commercial OfficerPast Role: Boehringer Ingelheim, Global Head Trade and Shopper Marketing
- David Wright: Chief Executive Officer
HRA Pharma, SA develops and commercializes drugs, devices, and services in the therapeutic areas of reproductive health and endocrine diseases. It offers reproductive health products, which include Norlevo for emergency contraception; Cicatridine for vaginitis and vaginal injury; Delidose, Divina, and Duova for HRT; GyMiso for cervical ripening;
and Mona Lisa, a copper contraceptive intrauterine device, as well as endocrinal products that include Lysodren and Lysosafe for adrenal cancer. The company also provides Bemedrex for asthma; Deprenyl for Parkinson's disease; and information and associated services for healthcare providers and other users. In addition, its development pipeline comprises ella/ellaOne, an emergency contraceptive pill; UPA UF, a treatment for uterine fibroids; UPA contraceptive products; Mifedren, a product candidate for a subset of Cushing's syndromes caused by ectopic ACTH(1) secretion; and cell-based therapies for muscle regeneration. The company distributes and markets its products directly in the European Union, including France, Germany, and the United Kingdom, as well as through license agreements in France and internationally. HRA Pharma, SA was founded in 1996 and is based in Paris, France. It has subsidiary locations in Bochum, Germany; London, the United Kingdom; and New York, New York.
